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Abstract
The aim of this study was to assess the agreements of both biplane and short-axis Simpson’s (SAX) methods for left atrial 
ejection fraction (LAEF) calculation utilising cardiovascular magnetic resonance imaging (CMR) in heart failure with 
preserved ejection fraction (HFpEF) and evaluate their relation to clinical outcomes. One hundred and thirty six subjects 
(HFpEF n = 97, controls n = 39) underwent CMR, six-minute walk tests and blood sampling in our prospective, observational, 
single-centre study. Overall, LAEF (%) was lower in HFpEF patients compared to controls (SAX 34 ± 13 vs 47 ± 8, biplane 
34 ± 16 vs 51 ± 11; p < 0.0001 for both). Atrial fibrillation (AF) was present in 24% of HFpEF and was associated with 
higher LA volumes and lower LAEF compared to sinus rhythm (p < 0.0001) with both methods. Biplane LAEF correlated 
strongly with SAX measurements (overall Pearson’s r = 0.851, sinus rhythm r = 0.651, AF r = 0.882; p < 0.0001). Biplane 
LAEF did not differ significantly compared to SAX LAEF (overall 34 ± 16 vs 34 ± 13%; p = 0.307) except in AF subjects 
in whom biplane LAEF was lower (mean difference 2 ± 4%, p = 0.013). There were 44 composite events (25 deaths, 19 HF 
hospitalizations) in HFpEF during median follow-up of 1429 days. LAEF below the median was associated with increased 
risk of composite endpoints (Log-Rank biplane p < 0.0001; SAX p = 0.009). In multivariable Cox proportional hazards 
regression analysis, both biplane LAEF (hazard ratio [HR] 0.604; 95% confidence interval [CI] (0.406–0.900); p = 0.013) 
and SAX LAEF (HR 0.636; CI 0.441–0.918; p = 0.016) remained independent predictors along with indexed extracellular 
volume. CMR LAEF, derived from either the short-axis or biplane method is lower in HFpEF compared to healthy controls 
and remains a strong marker of prognosis.
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Introduction
In our recently published article [1], we reported that car-
diovascular magnetic resonance (CMR) derived left atrial 
ejection fraction (LAEF) measured from the biplane method 
was lower in a well characterized cohort of heart failure with 
preserved ejection fraction (HFpEF) compared to healthy 
controls and was also independently associated with adverse 
outcomes. Furthermore, CMR biplane LAEF had excellent 
reproducibility. However, volumetric assessment of left 
atrial volumes (and hence function) derived from the short-
axis (Simpson’s short-axis [SAX]) method is widely recog-
nised as the imaging gold standard [2, 3]. In a recent study 
of HFpEF patients, the biplane method was shown to have 
good correlation and agreements for LA volumetric analy-
sis compared to the SAX method [4]. However, no prior 
CMR studies in HFpEF have compared LAEF between both 
methods. Furthermore, the prognostic role of SAX LAEF in 
HFpEF has not been reported. We aimed to assess the agree-
ments of both methods for LAEF (and LA volumes) utilising 
CMR in HFpEF. We also evaluated whether SAX LAEF is 
also related to clinical outcomes, in order to validate and 
strengthen our previous findings implicating CMR LAEF 
as a prognostic biomarker in HFpEF.
Methods
From our original study cohorts [1] of HFpEF (n = 140) and 
healthy controls (n = 48), paired data for image analysis of 
both CMR biplane and SAX LAEF derivation was available 
in 136 subjects (HFpEF n = 97, controls n = 39). HFpEF was 
defined as clinical or radiographic evidence of heart failure 
and left ventricular ejection fraction > 50%. Exclusion cri-
teria for HFpEF included: myocardial infarction in the pre-
ceding 6 months, suspected or confirmed cardiomyopathy or 
constrictive pericarditis, non-cardiovascular life expectancy 
< 6 months, severe chronic obstructive pulmonary disease 
(or forced expiratory volume  [FEV1] < 30% predicted or 
forced vital capacity [FVC] < 50% predicted), severe native 
valve disease and significant renal impairment (estimated 
glomerular filtration rate [eGFR] < 30 ml/min. The control 
population were age- and sex-matched compared to HFpEF 
and asymptomatic. As previously reported, hypertensive 
controls were also included since hypertension is highly 
prevalent in this age group of patients. Furthermore, hyper-
tension is intimately linked with HFpEF development and is 
also reportedly associated with LA dysfunction [5] and we 
wanted to account for this potential confounder.
Study recruitment, blood sampling, six-minute walk test-
ing, imaging protocols and analytical methods for CMR have 
been detailed previously. For the SAX method (see Fig. 1), a 
contiguous stack of short-axis steady-state-free-precession 
images were acquired with retrospective ECG gating (or 
prospective gating in subjects with AF). Both end-diastolic 
and end-systolic frames were contoured to derive maximal 
left atrial volume [LAV max] and minimal left atrial volume 
(LAV min) and LAEF was calculated. Unlike the biplane 
method (see Fig. 2), SAX volumes were inclusive of the 
LA appendage but both techniques excluded pulmonary 
veins. The primary endpoint remained the composite of 
all-cause mortality or first HF hospitalization. Parameters 
with univariable association with the composite endpoint at 
p < 0.1 was entered into Cox proportional hazards regression 
analysis. In cases of collinearity, variables with historically 
stronger prognostic importance from published literature 
were chosen for inclusion in Cox regression analysis and 
Fig. 1  Biplane method. Cine 2- (a) and 4-chamber (b) images illus-
trating contoured (yellow) left atrial areas for volume (and ejection 
fraction) derivation excluding the left atrial appendage and pulmo-
nary veins; LAA left atrial appendage; LSPV left superior pulmonary 
vein; RIPV right inferior pulmonary vein
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underwent stepwise elimination. Four separate clinically 
relevant Cox regression models were generated including 
a final model incorporating the strongest predictors. Cox 
regression models were limited to no more than 4 param-
eters (plus LAEF), allowing for approximately one param-
eter per 10 composite events. To allow hazard ratios (HR) to 
Fig. 2  Simpson’s short-axis method. Short-axis cine stack of images 
illustrating contoured (yellow) left atrial areas for volume (and ejec-
tion fraction) derivation inclusive of the left atrial appendage but 
excluding the pulmonary veins. LAA left atrial appendage, LSPV left 
superior pulmonary vein; LIPV left inferior pulmonary vein
Table 1  Baseline clinical 
characteristics
Values are mean ± SD, n (%) or median, interquartile range. The p values are for the t test or chi-square test
BNP B-type natriuretic peptide, COPD chronic obstructive pulmonary disease, HF heart failure, HFpEF 
heart failure with preserved ejection fraction, NA not applicable, NTpro-ANP N-terminal pro-atrial natriu-







 Age (years) 72 ± 10 73 ± 5 0.486
 Male (%) 52 (54) 18 (46) 0.682
Clinical
 Heart rate (beats per minute) 71 ± 14 68 ± 10 0.133
 Systolic blood pressure (mmHg) 145 ± 23 151 ± 24 0.155
 Diastolic blood pressure (mmHg) 74 ± 12 79 ± 10 0.012
 Body mass index (kg/m2) 34 ± 8 25 ± 3  < 0.0001
 Atrial fibrillation (%) 23 (24) 0 (0)  < 0.0001
 Prior HF hospitalization (%) 62 (64) 0 (0)  < 0.0001
 Diabetes (%) 55 (57) 0 (0)  < 0.0001
 Hypertension (%) 89 (92) 19 (49)  < 0.0001
 Angina (%) 15 (16) 0 (0) 0.004
 Known myocardial infarction (%) 12 (12) 0 (0) 0.011
 Asthma or COPD (%) 14 (14) 3 (8) 0.149
 TIA or CVA (%) 12 (12) 0 (0) 0.011
Functional status
 NYHA III/IV (%) 23 (24) NA –
 6MWT distance (m) 190 (130–275) 380 (340–440)  < 0.0001
 MLHF score 49 (24–65) NA –
Medications
 Betablocker (%) 67 (69) 2 (5)  < 0.0001
 ACEi or ARB (%) 86 (89) 9 (23)  < 0.0001
 Aldosterone antagonist (%) 30 (31) 0 (0)  < 0.0001
 Loop diuretic (%) 77 (79) 0 (0)  < 0.0001
Laboratory indices
 Urea (mmol/L) 9 ± 4 6 ± 1  < 0.0001
 Creatinine (umol/L) 92 (74–118) 67 (56–85)  < 0.0001
 Haemoglobin (g/L) 131 ± 23 140 ± 15 0.003
 BNP (ng/L) 117 (51–244) 33 (24–44)  < 0.0001
 NTpro-ANP (pg/ml) 6321 (3874) 4246 (3402–4532)  < 0.0001
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be compared according to one standard deviation increase, 
continuous predictor variables were Z-standardized. Event 
rates were calculated from Kaplan–Meier analysis. The Log-
Rank test was used to detect differences in survival curves. 
In order to further assess the strength of both biplane and 
SAX LAEF in predicting outcomes, receiver operator char-
acteristics (ROC) analyses were also performed.
Inter-technique comparison of both LAEF deriva-
tion methods included paired t-testing, regression and the 
Bland–Altman method. Ten randomly selected subjects 
were chosen to undergo intra-observer evaluation for both 
Table 2  Baseline imaging 
characteristics
ECV extracellular volume, iECV indexed to body surface area; extracellular volume, LA left atrium, LAEF 
left atrial ejection fraction, LAV max maximal left atrial volume, LAV min minimal left atrial volume, LV 
left ventricle, LVEDVI left ventricular end-diastolic volume indexed to body surface area, LVEF left ven-
tricular ejection fraction, LVESVI left ventricular end-systolic volume indexed to body surface area, MI 
myocardial infarction







 LVEF (%) 56 ± 5 58 ± 5 0.058
 LVEDVI (ml/m2) 79 ± 18 83 ± 14 0.237
 LVESVI (ml/m2) 35 ± 10 35 ± 8 0.950
 LV mass indexed (g/m2) 52 ± 15 46 ± 10 0.003
 LV mass/LVEDV 0.68 ± 0.16 0.57 ± 0.09  < 0.0001
 LV tissue characterisation
  Presence of MI (%) 13 (13) 0 (0) 0.007
  MI size (% of LV mass) 3.0 (0.9–4.9) NA –
  Presence of non-MI focal fibrosis (%) 38 (39) 5 (13) 0.007
  Non-MI fibrosis size (% of LV mass) 2.8 (1.2–6.6) 2.4 (0.6–3.6)  < 0.0001
  aNative myocardial T1 (ms) 1230 ± 78 1191 ± 98 0.038
  aPost-contrast myocardial T1 (ms) 457 ± 61 489 ± 93 0.007
  aECV (%) 28 ± 5 26 ± 3 0.008
  aiECV (ml/m2) 14 ± 4 11 ± 3 0.001
CMR LA parameters
 Overall—all subjects including atrial fibrillation
  SAX LAV max (ml) 120 ± 50 88 ± 21  < 0.0001
  SAX LAV min (ml) 84 ± 49 47 ± 14  < 0.0001
  SAX LAEF (%) 34 ± 13 47 ± 8  < 0.0001
  Biplane LAV max (ml) 102 ± 44 62 ± 22  < 0.0001
  Biplane LAV min (ml) 71 ± 44 31 ± 14  < 0.0001
  Biplane LAEF (%) 34 ± 16 51 ± 11  < 0.0001
 Sinus
  SAX LAV max (ml) 103 ± 33 88 ± 21 0.004
  SAX LAV min (ml) 64 ± 26 47 ± 14  < 0.0001
  SAX LAEF (%) 39 ± 10 47 ± 8  < 0.0001
  Biplane LAV max (ml) 88 ± 32 62 ± 22  < 0.0001
  Biplane LAV min (ml) 53 ± 25 31 ± 14  < 0.0001
  Biplane LAEF (%) 41 ± 12 51 ± 11  < 0.0001
 Atrial fibrillation
  SAX LAV max (ml) 175 ± 56 NA –
  SAX LAV min (ml) 148 ± 51 NA –
  SAX LAEF (%) 16 ± 8 NA –
  Biplane LAV max (ml) 147 ± 45 NA –
  Biplane LAV min (ml) 129 ± 43 NA –
  Biplane LAEF (%) 14 ± 9 NA –
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techniques, a minimum of 4 weeks apart. The two-way 
mixed-effect intraclass correlation co-efficient (ICC), coef-
ficient of variation (COV) and Bland–Altman analysis were 
used for test intra-observer agreements.
Results
Baseline clinical and imaging characteristics are shown in 
Tables 1 and 2. Both HFpEF and controls remained evenly 
matched for age (73 ± 8) and gender. HFpEF was associ-
ated with a high burden of co-morbidities including hyper-
tension, diabetes, anaemia and renal dysfunction. Atrial 
fibrillation (AF) was noted in 24% of HFpEF. Compared to 
controls, HFpEF was characterised by lower exercise capac-
ity, worse diastolic function (LA volumes, left ventricular 
mass, B-type natriuretic peptide [BNP] and N-terminal pro-
atrial natriuretic peptide [NT-proANP]), more prevalent 
focal (late gadolinium enhancement imaging) and diffuse 
fibrosis (extracellular volume and indexed extracellular vol-
ume [iECV]); p < 0.05 for all. Feasibility of image analysis 
for LA measures by both techniques was 100% in all sub-
jects. With both methods, HFpEF patients had lower LAEF 
(biplane 34 ± 16; SAX 34 ± 13) compared to controls: overall 
(biplane 51 ± 11, SAX 47 ± 8), with hypertension (biplane 
48 ± 12, SAX 45 ± 9) and without hypertension (biplane 
52 ± 9, SAX 49 ± 7); p < 0.0001 for all. No significant dif-
ferences in LAEF were noted between hypertensive and non-
hypertensive controls (biplane p = 0.222, SAX p = 0.119). 
Irrespective of methodology and cardiac rhythm, HFpEF 
was characterised by significantly higher LA volumes com-
pared to controls (p < 0.0001). HFpEF patients in AF had 
higher LA volumes and lower LAEF compared to sinus 
rhythm (p < 0.0001).
Biplane LA measures correlated strongly with SAX 
parameters overall (LAV max Pearson’s r = 0.910, LAV 
Table 3  Inter-technique 
agreements for left atrial 
volumes and ejection fraction 
between CMR short-axis and 
biplane methods
Abbreviations are as for Table 2






95% Limits of 
agreement
P value
All patients (n = 97)
 LAV max (ml) 120 ± 50 102 ± 44 18 ± 21 − 22 to 60 < 0.0001
 LAV min (ml) 84 ± 49 71 ± 44 13 ± 18 − 22 to 48 < 0.0001
 LAEF (%) 34 ± 13 34 ± 16 − 1 ± 8 − 17 to 15 0.307
Sinus rhythm (n = 74)
 LAV max (ml) 103 ± 33 88 ± 32 15 ± 13 − 9 to 41 < 0.0001
 LAV min (ml) 64 ± 26 53 ± 25 11 ± 10 − 9 to 31 < 0.0001
 LAEF (%) 39 ± 10 41 ± 12 − 2 ± 9 − 20 to 16 0.083
Atrial fibrillation (n = 23)
 LAV max (ml) 176 ± 56 147 ± 45 27 ± 35 − 42 to 97 0.001
 LAV min (ml) 148 ± 51 129 ± 43 19 ± 32 − 43 to 81 0.008
 LAEF (%) 16 ± 8 14 ± 9 2 ± 4 − 6 to 10 0.013
Table 4  Intra-observer 
assessments for left atrial 
volumes and ejection fraction
Abbreviations are as for Table 2

















  LAV max (ml) 123 ± 40 122 ± 39 1 ± 3 0.99 0.01 3 − 7 to 5
  LAV min (ml) 85 ± 44 84 ± 43 1 ± 2 0.99 0.01 2 − 4 to 3
  LAEF (%) 34 ± 14 34 ± 14 0 ± 2 0.99 0.01 6 − 4 to 4
 Biplane
  LAV max (ml) 99 ± 48 101 ± 49 2 ± 5 0.99 0.01 4.8 − 7 to 12
  LAV min (ml) 70 ± 45 71 ± 44 1 ± 4 0.99 0.01 5.4 − 7 to 8
  LAEF (%) 33 ± 13 33 ± 13 0.1 ± 3 0.98 0.02 9.4 − 6 to 6
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min r = 0.884, LAEF r = 0.851), in sinus rhythm (LAV max 
0.926, LAV min r = 0.920, LAEF r = 0.651) and moderate to 
good in AF (LAV max r = 0.776, LAV min r = 0.788, LAEF 
r = 0.882); p < 0.0001 for all. LA volumes calculated from 
the biplane method (excluding the LA appendage) were sig-
nificantly lower compared to the SAX method overall and 
irrespective of whether subjects were in sinus rhythm or AF 
(Table 2). While overall agreements for LA volumes were 
good (Table 3), the limits of agreement were wider in AF. 
Biplane LAEF did not differ significantly compared to SAX 
LAEF except in AF subjects in whom biplane LAEF was 
comparably lower (mean difference 2 ± 4%, p = 0.013). Intra-
observer agreements for both methods were excellent, albeit 
biplane measures fared slightly worse (Table 4). 
Forty four composite events (45%, 25 deaths, 19 HF hos-
pitalizations) were observed in the HFpEF group during 
median follow-up of 1429 days (1157–1657). Sixteen param-
eters were associated with outcomes during Cox regression 
analysis, including both biplane and SAX LAEF (Table 5). 
Urea and extracellular volume (ECV) were excluded from 
regression analysis due to collinearity. On Cox regression 
analysis (Table 6), both biplane and SAX LAEF remained 
significantly associated with outcome in 3 separate mod-
els incorporating clinical factors, biochemical markers 
and imaging parameters. In a final model comprising the 
strongest predictors overall, biplane LAEF (HR 0.604; 95% 
confidence interval [CI] (0.406–0.900); p = 0.013) and SAX 
LAEF (HR 0.636; CI 0.441–0.918; p = 0.016) remained 
independent predictors along with indexed extracellular vol-
ume (iECV). Irrespective of methodology, a lower LAEF 
group (below median) was associated with increased risk 
of the composite endpoint (biplane Log-Rank p < 0.0001; 
SAX Log-Rank p = 0.009); see Fig. 3. The area under curve 
for predicting outcomes was higher for SAX LAEF (0.709, 
p < 0.0001), albeit not significantly different compared to 
biplane LAEF (0.690, p = 0.001).
Discussion
Our study is the first to compare the agreements of both 
CMR biplane and SAX LAEF in HFpEF and assess their 
prognostic capabilities in the same setting. Our results 
confirm LAEF as an independent marker of prognosis in 
HFpEF, irrespective of CMR technique and validate our 
earlier findings of biplane LAEF as a strong prognostic bio-
marker [1]. The ability of CMR LAEF to be measured via 2 
separate methods with a high degree of precision and repro-
ducibility in addition to its prognostic capabilities are impor-
tant strengths for consideration when being proposed as an 
imaging biomarker [6]. While CMR SAX LAEF is consid-
ered the more accurate of both measures [2, 3], the CMR 
biplane method represents a potentially useful alternative for 
both research and clinical settings in HFpEF and has been 
recently proposed as the preferred method of LA volumet-
ric analysis in an expert consensus document by the Euro-
pean Association of Cardiovascular Imaging [7]. Biplane 
LAEF derivation does not necessitate additional, multiple 
short axis image acquisitions which can prolong scan times 
in predominantly elderly subjects typical of HFpEF, who 
may struggle with multiple breath-holds. Furthermore, 
image analysis of the biplane method is also significantly 
shorter. On the other hand, SAX LAEF is an alternative if 
long axis images are degraded by artefact. Our findings are 
also important since LAEF represents a potential therapeutic 
target in HFpEF [8] where there are currently no effective 
therapies [9] and may also act as a trial endpoint [10].
While LA volumes were underestimated by the biplane 
method compared to SAX evaluation, LAEF did not differ 
significantly except in AF. Since LAEF is a fraction derived 
from volumetric analysis, systematic bias of similar mag-
nitudes in the same direction i.e. underestimation of both 
LAV max and LAV min likely explains this lack of LAEF 
difference between both the techniques. The difference in 
Table 5  Unadjusted predictors for the composite endpoint of death 
and/or hospitalization with heart failure
Abbreviations are as for Tables 1 and 2; Hazard ratios are based upon 
one standard deviation increase in the predictor variable for continu-
ous variables which are Z-standardized
CI confidence interval; LAVI max left atrial maximal volume indexed 
to body surface area
a Parameters not entered into multivariable analysis
Unadjusted predictors of outcome
Hazard ratio (95%CI) P value
Clinical
 Age (years) 1.630 (1.203–2.210) 0.002
 Average diastolic BP (mmHg) 0.562 (0.388–0.814) 0.002
 Prior HF hospitalization 2.236 (1.104–4.529) 0.025
 6MWT distance (m) 0.545 (0.339–0.876) 0.012
Clinical blood samples
 aUrea (mmol/L) 1.284 (1.002–1.644) 0.048
 Log creatinine (umol/L) 1.352 (1.024–1.784) 0.033
 Haemoglobin (g/L) 0.766 (0.576–1.019) 0.067
 Log BNP (ng/L) 1.542 (1.086–2.189) 0.016
 NTpro-ANP (pg/ml) 1.551 (1.113–2.160) 0.009
Imaging (CMR)
 LV mass index (g/m2) 1.432 (1.020–2.010) 0.038
 LAVI max (ml/m2) 1.595 (1.202–2.115) 0.001
 LGE MI (%) 1.687 (0.784–3.632) 0.181
 aECV (%) 1.822 (1.173–2.831) 0.008
 iECV (ml/m2) 1.558 (1.097–2.213) 0.013
 Biplane LAEF (%) 0.575 (0.419–0.788) 0.001
 SAX LAEF (%) 0.596 (0.447–0.794) 0.0001
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LA volumes between both methods however is unsurpris-
ing given that the LA appendage is typically excluded from 
the biplane method but included in the SAX method [2, 3]. 
These volumetric differences are likely further exaggerated 
in HFpEF where LA dilation is typical [2, 4] and associ-
ated with a higher prevalence of AF. Furthermore, in AF we 
Table 6  Multiple Cox regression models inclusive of biplane and SAX LAEF for the composite endpoint of death and/or hospitalization with 
heart failure
Cox proportional hazard regression predictors of outcome
Including biplane LAEF Including SAX LAEF
Hazard ratio (95%CI) P value Hazard ratio (95%CI) P value
Clinical
 Age 1.126 (0.771–1.645) 0.538 Age 1.049 (0.708–1.555) 0.811
 Average diastolic BP 0.606 (0.407–0.904) 0.014 Average diastolic BP 0.580 (0.390–0.863) 0.007
 Prior HF hospitalization 1.693 (0.810–3.540) 0.162 Prior HF hospitalization 1.588 (0.754–3.347) 0.224
 6MWT distance 0.596 (0.372–0.956) 0.032 6MWT distance 0.613 (0.387–0.972) 0.038
 + Biplane LAEF 0.535 (0.385–0.744)  < 0.0001  + SAX LAEF 0.532 (0.391–0.724)  < 0.0001
Clinical blood samples
 Log creatinine (umol/L) 1.035 (0.731–1.466) 0.0847 Log creatinine (umol/L) 1.033 (0.734–1.454) 0.853
 Haemoglobin (g/L) 0.805 (0.584–1.109) 0.155 Haemoglobin (g/L) 0.677 (0.496–0.923) 0.114
 Log BNP (ng/L) 1.126 (0.712–1.782) 0.611 Log BNP (ng/L) 1.128 (0.712–1.787) 0.607
 Log NTpro-ANP 1.373 (0.990–1.906) 0.058 NTpro-ANP 1.244 (0.890–1.739) 0.202
 + Biplane LAEF 0.649 (0.456–0.924) 0.016  + SAX LAEF 0.552 (0.410–0.741)  < 0.0001
Imaging
 LV mass index 0.582 (0.217–1.560) 0.282 LV mass index 0.529 (0.205–1.366) 0.188
 LAVI max 0.961 (0.599–1.541) 0.869 LAVI max 0.997 (0.630–1.577) 0.988
 iECV 1.558 (1.097–2.213) 0.013 iECV 1.564 (1.106–2.211) 0.011
 + Biplane LAEF 0.575 (0.419–0.788) 0.001  + SAX LAEF 0.668 (0.472–0.944) 0.022
Strongest markers combined
 Average diastolic BP 0.723 (0.461–1.134) 0.158 Average diastolic BP 0.725 (0.461–1.139) 0.163
 6MWT distance 0.611 (0.354–1.053) 0.076 6MWT distance 0.592 (0.346–1.011) 0.055
 iECV 1.491 (1.038–2.143) 0.031 iECV 1.584 (1.110–2.260) 0.011
 + Biplane LAEF 0.604 (0.406–0.900) 0.013  + SAX LAEF 0.636 (0.441–0.918) 0.016
Fig. 3  Survival analysis stratified according to median left atrial ejec-
tion fraction. Kaplan–Meier analysis stratified according to median 
left atrial ejection fraction for the composite endpoint of death and/
or hospitalization with heart failure using the biplane method (left 
panel) and the short-axis method (right panel)
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employed prospective gating which can lower the margins 
for erroneous measurements. As addressed in our recent 
publication, we also recognise that having some subjects 
with hypertension in our control group is a limitation given 
that these subjects were not totally free from cardiovascular 
disease. However, LAEF was again lower in HFpEF with 
either methodology, irrespective of controls’ hypertensive 
status, reinforcing altered LA contractile function in the 
pathophysiology of HFpEF.
Conclusions
CMR LAEF calculated from either the short-axis or biplane 
method has excellent reproducibility and remains a strong 
marker of prognosis in HFpEF.
Acknowledgements The authors would like to thank the CMR radiog-
raphers at Glenfield Hospital for image acquisition and Bristol Myers 
Squibb, in particular Jing Yang and Lei Zhao for facilitating plasma 
biomarker (NTpro-ANP) analysis.
Author contributions PK recruited the patients, supervised the study 
visits and CMR scans (with AS and JNK), analysed the data, performed 
the statistical analysis and drafted the initial manuscript along with 
JRA. GGS undertook follow-up outcome data collection. BNP and 
other serum sampling were undertaken in the hospital pathology labo-
ratory under the supervision of PG. PK, IBS, LLN and GPM conceived 
the study. All authors critically revised the manuscript for important 
intellectual content, approved the final version for submission and 
agree to be accountable for all aspects of the work in ensuring that 
questions relating to the accuracy or integrity of any part of the work 
are appropriately investigated and resolved.
Funding This work was supported by the National Institute for Health 
Research (NIHR) Leicester Cardiovascular Biomedical Research Cen-
tre overall project Grant: IRS_BRU_0211_20033 and the John and 
Lucille Van Geest Foundation. Professor GPM was supported by NIHR 
Research Fellowships (PDF-2011-0451 and CDF 2014-07-045).
Compliance with ethical standards 
Conflicts of interest Lei Zhao and Jing Yang are employees of Bris-
tol Myers Squibb which facilitated plasma NTpro-ANP analysis. All 
authors declare that they have no competing interests relevant to this 
study. All authors also state that they have full control of all primary 
data and that they agree to allow the journal to review their data if 
requested.
Ethical approval The study was approved by the United Kingdom 
National Research Ethics Service Committee East Midlands—Not-
tingham (reference: 12/EM/0222). Informed consent was obtained 
from all individual participants included in the study. The study was 
performed in accordance with the ethical standards laid down in the 
1964 Declaration of Helsinki and its later amendments.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References
 1. Kanagala P, Arnold JR, Cheng ASH et al (2019) Left atrial ejec-
tion fraction and outcomes in heart failure with preserved ejection 
fraction. Int J Cardiovasc Imaging. https ://doi.org/10.1007/s1055 
4-019-01684 -9
 2. Hudsmith LE, Cheng AS, Tyler DJ et al (2007) Assessment of left 
atrial volumes at 15 Tesla and 3 Tesla using FLASH and SSFP 
cine imaging. J Cardiovasc Magn Reson 9(4):673–679. https ://
doi.org/10.1080/10976 64060 11388 05
 3. Maceira AM, Cosin-Sales J, Roughton M et al (2010) Reference 
left atrial dimensions and volumes by steady state free precession 
cardiovascular magnetic resonance. J Cardiovasc Magn Reson 
12:65. https ://doi.org/10.1186/1532-429X-12-65
 4. Vassiliou VS, Patel HC, Rosen SD et al (2016) Left atrial dila-
tion in patients with heart failure and preserved ejection fraction: 
Insights from cardiovascular magnetic resonance. Int J Cardiol 
210:158–160. https ://doi.org/10.1016/j.ijcar d.2016.02.101
 5. Mondillo S, Cameli M, Caputo ML et al (2011) Early detection 
of left atrial strain abnormalities by speckle-tracking in hyper-
tensive and diabetic patients with normal left atrial size. J Am 
Soc Echocardiogr 24(8):898–908. https ://doi.org/10.1016/j.
echo.2011.04.014
 6. Vasan RS (2006) Biomarkers of cardiovascular disease: molecu-
lar basis and practical considerations. Circulation 113(19):2335–
2362. https ://doi.org/10.1161/CIRCU LATIO NAHA.104.48257 0
 7. Petersen SE, Khanji MY, Plein S et al (2019) European Associa-
tion of Cardiovascular Imaging expert consensus paper: a com-
prehensive review of cardiovascular magnetic resonance normal 
values of cardiac chamber size and aortic root in adults and rec-
ommendations for grading severity. Eur Heart J Cardiovasc Imag-
ing. https ://doi.org/10.1093/ehjci /jez23 2
 8. Shah SJ, Feldman T, Ricciardi MJ et al (2018) One-year safety 
and clinical outcomes of a transcatheter interatrial shunt device 
for the treatment of heart failure with preserved ejection fraction 
in the reduce elevated left atrial pressure in patients with heart 
failure (REDUCE LAP-HF I) Trial: a randomized clinical trial. 
JAMA Cardiol 3(10):968–977. https ://doi.org/10.1001/jamac ardio 
.2018.2936
 9. Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guide-
lines for the diagnosis and treatment of acute and chronic heart 
failure: the task force for the diagnosis and treatment of acute 
and chronic heart failure of the European Society of Cardiology 
(ESC)Developed with the special contribution of the Heart Failure 
Association (HFA) of the ESC. Eur Heart J 37(27):2129–2200. 
https ://doi.org/10.1093/eurhe artj/ehw12 8
 10. Lewis GA, Schelbert EB, Naish JH et al (2019) Pirfenidone in 
heart failure with preserved ejection fraction-rationale and design 
of the PIROUETTE trial. Cardiovasc Drugs Ther. https ://doi.
org/10.1007/s1055 7-019-06876 -y
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
